Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis

Koji Sasaki, Hagop M. Kantarjian, Kiyomi Morita, Nicholas J. Short, Marina Konopleva, Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Sa Wang, Joseph D. Khoury, Jeffrey L. Jorgensen, Richard E. Champlin, Issa F. Khouri, Partow Kebriaei, Heather M. Schroeder, Maria Khouri, Rebecca Garris, Koichi Takahashi, Susan M. O’Brien, Elias J. Jabbour

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences